Waxaa qoray Qoraa Shaqaalaha Daryeelka Caafimaadka NS 16 Maajo 2022
Mounjaro waxa lagu bixin doonaa lix qiyaasood, 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, iyo 15mg, oo ay weheliso qalinka iswada ee Lilly ee la socda irbad qarsoon oo horay loogu xidhay.
Mounjaro waa GIP iyo GLP-1 agonist receptor ah.(Credit: Lilly USA, LLC.)
Shirkadda Eli Lilly iyo (Lilly) waxay heshay oggolaanshaha Maamulka Cuntada iyo Dawooyinka ee Maraykanka (FDA) ee duritaankeeda Mounjaro (tirzepatide) si loogu daweeyo nooca 2 ee sonkorowga ee dadka waaweyn.
Mounjaro waa hal unug oo dhaqaajiya hormoonnada incretin ee dabiiciga ah gulukoos-ku-tiirsan insulinotropic polypeptide (GIP) iyo glucagon-like peptide-1 (GLP-1) agonist receptor.
Daawada waxaa lagu tilmaamaa daawaynta todobaadkiiba hal mar, oo la socota cuntada iyo jimicsiga si loo hagaajiyo xakamaynta glycemic ee dadka qaangaarka ah ee qaba nooca 2 ee sonkorowga.
Lilly waxay siin doontaa Mounjaro, kii ugu horreeyay oo kaliya ee FDA ogolaatay GIP iyo GLP-1 agonist receptor, lix qiyaasood, oo ay ku jiraan 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, iyo 15mg.
Shirkaddu waxay qorshaynaysaa inay dawadan ku iibiso gudaha Maraykanka, iyada oo ay weheliso qalinkeeda auto-injector kaas oo la socda irbad qarsoon oo hore loogu xidhay, dhawr toddobaad gudahood.
Madaxwaynaha Lilly Diabetes Mike Mason ayaa yiri: "Lilly waxay leedahay ku dhawaad 100-sano oo dhaxal ah oo ah horumarinta daryeelka dadka la nool cudurka macaanka - waligeed ma dejiyo natiijooyinka hadda jira.
"Kuma qanacsanayn innagoo og in kala badh in ka badan 30 milyan oo Maraykan ah oo qaba nooca 2aad ee xanuunka macaanka aanay gaadhin heerarkii gulukoosta dhiigga ee ay bartilmaameedsanayeen.
"Waan ku faraxsanahay inaan soo bandhigno Mounjaro, kaas oo matalaya fasalka cusub ee nooca 2 ee daawaynta sonkorowga ee la soo bandhigay ku dhawaad toban sano wuxuuna qeexayaa hadafkeena ah inaan u keeno daawayn cusub oo cusub bulshada sonkorowga."
Oggolaanshaha FDA ee Mounjaro wuxuu ku salaysan yahay natiijooyinka wajiga 3 barnaamijka SURPASS ee bilaabmay dabayaaqadii 2018, oo ka kooban shan tijaabo oo caalami ah iyo laba tijaabo oo goboleed oo Japan ah.
Barnaamijku wuxuu qiimeeyay waxtarka iyo badbaadada Mounjaro 5mg, 10mg iyo 15mg sida monotherapy, iyo sidii lagu daro daawooyinka kala duwan ee daryeelka-daryeelka nooca 2 ee sonkorowga.
Barnaamijka SURPASS, Mounjaro 5mg waxay keentay hoos u dhaca A1C 1.8% ilaa 2.1%, iyo Mounjaro 10mg iyo Mounjaro 15mg labaduba waxay gacan ka geysteen dhimista 1.7% iyo 2.4% A1C.
Daawada looma tilmaamin miisaan lumis;si kastaba ha ahaatee, ka qaybgalayaasha lagu daweeyay Mounjaro waxay lumiyeen 12lb (5mg) ilaa 25lb (15mg) miisaan celcelis ahaan, ayay tiri shirkaddu.
Isbeddelka celceliska miisaanka jidhka wuxuu ahaa mid ka mid ah qodobbada ugu dambeeya ee muhiimka ah ee dhammaan daraasadaha SURPASS.
Bukaan-socodka lagu daweeyay Mounjaro ayaa soo sheegay waxyeellooyin ay ka mid yihiin lallabbo, shuban, rabitaanka cuntada oo yaraada, matag, calool-istaag, dyspepsia, iyo calool xanuun.
Intaa waxaa dheer, Mounjaro waxay la socotaa Digniin Sanduuqan oo ku saabsan burooyinka C-cell tayroodh.Daawadu waa ka mamnuuc bukaanada leh taariikhda shakhsi ahaaneed ama qoyska ee kansarka tayroodhka medullary ama bukaanada qaba Multiple Endocrine Neoplasia syndrome nooca 2.
Mounjaro laguma qiimayn bukaanada leh taariikh xanuunka pankreatit lamana tilmaamin in loo isticmaalo bukaanada qaba nooca 1-aad ee sonkorowga, ayuu yidhi.Lilly.
Waqtiga boostada: May-24-2022